Effect of saxagliptin on the expression of HIF‑1α in the liver of diabetic rats with fatty liver

Zhao,Qian; Xiao,Qian; Meng,Xiangying; Chen,Jianyang; Ye,Weiwei; Zhou,Yong

doi:10.3892/etm.2018.6473

Effect of saxagliptin on the expression of HIF‑1α in the liver of diabetic rats with fatty liver

Authors:
- Qian Zhao
- Qian Xiao
- Xiangying Meng
- Jianyang Chen
- Weiwei Ye
- Yong Zhou
View Affiliations

Affiliations: Department of Endocrinology, Dahua Hospital of Xuhui District, Shanghai 200237, P.R. China
Published online on: July 18, 2018 https://doi.org/10.3892/etm.2018.6473
Pages: 2559-2563
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to establish a rat model of type 2 diabetes mellitus (T2DM) complicated with fatty liver and to detect the expression of hypoxia‑inducible factor‑1α (HIF‑1α) in liver tissue during the treatment with saxagliptin. Eighty male Wistar rats were randomly divided into two groups. One group was fed with high fat diet to establish T2DM model (n=40), and the other group was fed normally to serve as the control group (n=40). Successfully established rat T2DM models were randomly divided into two groups: The treatment group that received intraperitoneal injection of saxagliptin solution and the other the model group with normal breeding. Blood glucose, blood lipid, liver function and the expression of HIF‑1α in liver tissue were detected. Levels of blood glucose in model treatment group were significantly higher than those in the control group (p<0.05). Levels of total cholesterol (TC), triglyceride (TG), low‑density lipoprotein cholesterol (LDL‑C), high‑density lipoprotein cholesterol (HDL‑C), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ‑glutamyl transferase (GGT) in model and treatment group were significantly higher than those in control group (p<0.05), but were significantly reduced with the prolonged treatment (p<0.05). Levels of TC, TG, LDL‑C, HDL‑C, AST, ALT and GGT and expression level of HIF‑1α were significantly higher in the model group than in control group before 3 weeks of treatment (p<0.05), but no significant differences were found after 3 weeks of treatment (p>0.05). Expression level of HIF‑1α was decreased with the prolonged treatment, and no significant difference in expression level of HIF‑1α was found 3 weeks after treatment (p>0.05). In conclusion, HIF‑1α is highly expressed in rats with T2DM and fatty liver. Saxagliptin can effectively improve blood glucose, blood lipid and liver function and reduce the protein expression of HIF‑1α in diabetic rats with fatty liver.

View Figures

View References

1	American Diabetes Association, : Standards of medical care in diabetes-2017 abridged for primary care providers. Clin Diabetes. 35:5–26. 2017.PubMed/NCBI
2	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al: EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128. 2015. View Article : Google Scholar : PubMed/NCBI
3	Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al TECOS Study Group, : Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 373:232–242. 2015. View Article : Google Scholar : PubMed/NCBI
4	American Diabetes Association, : 2. Classification and diagnosis of diabetes. Diabetes Care. 40 Suppl 1:S11–S24. 2017. View Article : Google Scholar : PubMed/NCBI
5	Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al LEADER Steering Committee, ; LEADER Trial Investigators, : Liraglutide and cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 375:311–322. 2016. View Article : Google Scholar : PubMed/NCBI
6	Byrne CD and Targher G: EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: Is universal screening appropriate? Diabetologia. 59:1141–1144. 2016. View Article : Google Scholar : PubMed/NCBI
7	Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, Contos MJ, Shiffman ML, Stravitz RT, Sterling RK, et al: The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 46:1091–1100. 2007. View Article : Google Scholar : PubMed/NCBI
8	Mehrabani M, Najafi M, Kamarul T, Mansouri K, Iranpour M, Nematollahi MH, Ghazi-Khansari M and Sharifi AM: Deferoxamine preconditioning to restore impaired HIF-1α-mediated angiogenic mechanisms in adipose-derived stem cells from STZ-induced type 1 diabetic rats. Cell Prolif. 48:532–549. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chen H, Jia P, Kang H, Zhang H, Liu Y, Yang P, Yan Y, Zuo G, Guo L, Jiang M, et al: Upregulating HIF-1α by hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wound. Adv Healthc Mater. 5:907–918. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sunkari VG, Lind F, Botusan IR, Kashif A, Liu ZJ, Ylä-Herttuala S, Brismar K, Velazquez O and Catrina SB: Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair Regen. 23:98–103. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lonardo A, Ballestri S, Marchesini G, Angulo P and Loria P: Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis. 47:181–190. 2015. View Article : Google Scholar : PubMed/NCBI
12	Oei L, Rivadeneira F, Zillikens MC and Oei EH: Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 13:106–115. 2015. View Article : Google Scholar : PubMed/NCBI
13	Asrih M and Jornayvaz FR: Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol. 418:55–65. 2015. View Article : Google Scholar : PubMed/NCBI
14	Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, et al: Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 47:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
15	Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 12:5447–5454. 1992. View Article : Google Scholar : PubMed/NCBI
16	Balamurugan K: HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, Gilkes DM, He J and Semenza GL: HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci USA. 112:E6215–E6223. 2015. View Article : Google Scholar : PubMed/NCBI
18	Nayak BK, Shanmugasundaram K, Friedrichs WE, Cavaglierii RC, Patel M, Barnes J and Block K: HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes. 65:1387–1397. 2016. View Article : Google Scholar : PubMed/NCBI
19	Dodd KM, Yang J, Shen MH, Sampson JR and Tee AR: mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 34:2239–2250. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, De Marco P, Cirillo F, Cappello AR, Dolce V, Belfiore A, et al: Copper activates HIF-1α/GPER/VEGF signalling in cancer cells. Oncotarget. 6:34158–34177. 2015. View Article : Google Scholar : PubMed/NCBI
21	Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, et al: Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: A retrospective cohort study. Ann Intern Med. 164:705–714. 2016. View Article : Google Scholar : PubMed/NCBI
22	Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, et al LEAN trial team, : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 387:679–690. 2016. View Article : Google Scholar : PubMed/NCBI
23	Dyson JK, Anstee QM and McPherson S: Non-alcoholic fatty liver disease: A practical approach to treatment. Frontline Gastroenterol. 5:277–286. 2014. View Article : Google Scholar : PubMed/NCBI